What Changes To The AI Act Would Benefit Medtech Most?

With the European Commission’s AI Act now in the final negotiation phase, industry bodies MedTech Europe and COCIR have outlined several areas where the draft text could be altered to optimize the potential of AI in health care.

AI Legislation
• Source: Shutterstock

European trade bodies MedTech Europe and COCIR have co-signed a letter with 11 other health organizations urging EU policymakers to “strongly consider” the impact the Artificial Intelligence (AI) Act proposal will have on the EU health ecosystem while firming up details of the final legislation.

Key Takeaways

Trilogue negotiations between the European Parliament, Commission and Council on the content of the draft AI Act began last month and represent the final opportunity for changes to be agreed to the draft text before the legislation is adopted.

During this process, the three entities will present their own versions of the draft text, and eventually reach a decision on the final unified version.

These discussions may go on for some 12-18 months, depending on how long it takes for an agreement to be reached on the details of the proposal.(Also see "

A key priority during these trilogues, the stakeholders say in their letter, is ensuring the AI Act is aligned with existing regulations, including sectoral legislation under the MDR and IVDR

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.